Osteoporosis, Postmenopausal

12
Pipeline Programs
6
Companies
15
Clinical Trials
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
3
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
571%
Monoclonal Antibody
229%
+ 5 programs with unclassified modality

On Market (5)

Approved therapies currently available

U
ACTONELApproved
risedronate sodium
Unknown Company
oral1998
U
ATELVIAApproved
risedronate sodium
Unknown Company
oral2010
Eli Lilly and Company
FORTEOApproved
teriparatide
Eli Lilly and Company
Parathyroid Hormone Analog [EPC]subcutaneous2002
U
RISEDRONATE SODIUMApproved
risedronate sodium
Unknown Company
oral2016
Radius Health
TYMLOSApproved
abaloparatide
Radius Health
Parathyroid Hormone-Related Peptide Analog [EPC]subcutaneous2017

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
4 programs
1
1
1
teriparatidePhase 4Peptide1 trial
teriparatidePhase 3Peptide1 trial
BlosozumabPhase 1Monoclonal Antibody1 trial
TeriparatideN/APeptide1 trial
Active Trials
NCT00696644Completed794Est. Apr 2011
NCT02109042Completed15Est. Jul 2014
NCT00046137Completed
+1 more trials
Radius Health
Radius HealthMA - Boston
3 programs
1
1
Denosumab InjectionPhase 41 trial
AbaloparatidePhase 3Peptide1 trial
AbaloparatideN/APeptide1 trial
Active Trials
NCT04974723CompletedEst. Sep 2021
NCT03710889CompletedEst. Jul 2020
NCT04467983Active Not RecruitingEst. Dec 2026
Sanofi
SanofiPARIS, France
1 program
1
Risedronate SodiumPhase 44 trials
Active Trials
NCT00460733Completed141Est. Sep 2011
NCT00632216Completed464Est. May 2006
NCT00549965Completed202
+1 more trials
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
AVT03Phase 31 trial
Active Trials
NCT05395091Completed532Est. Oct 2024
Bayer
BayerLEVERKUSEN, Germany
2 programs
E2 transdermalN/A2 trials
E2/LNG oralN/A1 trial
Active Trials
NCT01397955Completed148Est. Apr 2014
NCT01386281Completed506Est. Apr 2014
NCT01401114Completed411Est. Sep 2014
One Biosciences
One BiosciencesFrance - Paris
1 program
DenosumabN/AMonoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Radius HealthDenosumab Injection
SanofiRisedronate Sodium
SanofiRisedronate Sodium
SanofiRisedronate Sodium
SanofiRisedronate Sodium
Eli Lilly and Companyteriparatide
AlvotechAVT03
Radius HealthAbaloparatide
Eli Lilly and CompanyBlosozumab
Radius HealthAbaloparatide
BayerE2/LNG oral
BayerE2 transdermal
BayerE2 transdermal
Eli Lilly and CompanyTeriparatide

Clinical Trials (15)

Total enrollment: 5,976 patients across 15 trials

NCT04467983Radius HealthDenosumab Injection

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Start: Feb 2021Est. completion: Dec 2026
Phase 4Active Not Recruiting
NCT00460733SanofiRisedronate Sodium

SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.

Start: Mar 2007Est. completion: Sep 2011141 patients
Phase 4Completed
NCT00632216SanofiRisedronate Sodium

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

Start: May 2004Est. completion: May 2006464 patients
Phase 4Completed
NCT00549965SanofiRisedronate Sodium

Satisfaction and Compliance of Risedronate in PMO

Start: Oct 2003202 patients
Phase 4Completed
NCT00549068SanofiRisedronate Sodium

POWER Point of Care Effect on Satisfaction of Treatment

Start: Feb 2003Est. completion: Nov 20042,433 patients
Phase 4Completed

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Start: Oct 2001Est. completion: Jul 2005330 patients
Phase 4Completed

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

Phase 3Completed

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

Start: Aug 2022Est. completion: Oct 2024532 patients
Phase 3Completed

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

Start: Sep 2018Est. completion: Jul 2020
Phase 3Completed

A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants

Start: Apr 2014Est. completion: Jul 201415 patients
Phase 1Completed

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Start: Jul 2021Est. completion: Sep 2021
N/ACompleted
NCT01401114BayerE2/LNG oral

Wellnara Post-marketing Surveillance in Japan

Start: Mar 2009Est. completion: Sep 2014411 patients
N/ACompleted
NCT01397955BayerE2 transdermal

Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan

Start: Jan 2009Est. completion: Apr 2014148 patients
N/ACompleted
NCT01386281BayerE2 transdermal

Julina Post-marketing Surveillance for Climacteric Symptoms in Japan

Start: Oct 2008Est. completion: Apr 2014506 patients
N/ACompleted

A Study for Teriparatide in Severe Osteoporosis

Start: Jun 2008Est. completion: Apr 2011794 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
Peptide is the dominant modality (71% of programs)
6 companies competing in this space